Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact: Problem Solving01:26

Impact: Problem Solving

In an experiment conducted during a Mars mission, a rover propels a projectile with an initial velocity, and the projectile rebounds after colliding with the Martian surface. To ascertain the maximum height attained by the projectile after this collision, the known restitution coefficient and acceleration due to gravity are employed.
By designating the launch point as the origin and utilizing kinematic equations, the vertical component of the projectile's velocity at the point of impact is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Leukemia & lymphoma·2026
Same author

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Blood neoplasia·2026
Same author

Detection and classification of lymphoma from cell-free methylome data.

NPJ precision oncology·2026
Same author

Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario.

Blood neoplasia·2026
Same author

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Hematological oncology·2026
Same author

Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy.

Practical radiation oncology·2026
Same journal

Decentralized Clinical Trials in Hematology: the Promise and the Peril.

Blood·2026
Same journal

How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

Blood·2026
Same journal

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026
Same journal

Precision Transfusion Medicine in the Omics Era.

Blood·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Hitting the target in MCL.

Michael Crump1

  • 1Princess Margaret Hospital.

Blood
|May 19, 2012
PubMed
Summary
This summary is machine-generated.

Evaluating new lymphoma therapies is challenging. Combining fluorothymidine–positron emission tomography (FLT-PET) imaging and immunohistochemistry effectively shows how cyclin-dependent kinase (cdk) inhibitors impact tumor cells in mantle cell lymphoma.

More Related Videos

An Emerging Target Paradigm to Evoke Fast Visuomotor Responses on Human Upper Limb Muscles
09:27

An Emerging Target Paradigm to Evoke Fast Visuomotor Responses on Human Upper Limb Muscles

Published on: August 25, 2020

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Related Experiment Videos

Last Updated: May 22, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

An Emerging Target Paradigm to Evoke Fast Visuomotor Responses on Human Upper Limb Muscles
09:27

An Emerging Target Paradigm to Evoke Fast Visuomotor Responses on Human Upper Limb Muscles

Published on: August 25, 2020

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Area of Science:

  • Oncology
  • Hematology
  • Pharmacodynamics

Background:

  • Evaluating novel therapies for hematologic malignancies, including lymphoma, requires robust methods to assess biomarker and pharmacodynamic changes within tumor cells.
  • Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with limited treatment options for relapsed disease.

Discussion:

  • Leonard et al. investigated the cyclin-dependent kinase (cdk) inhibitor PD0332991 in patients with relapsed MCL.
  • The study highlights the utility of combining functional imaging, specifically fluorothymidine–positron emission tomography (FLT-PET), with immunohistochemistry.
  • This combined approach provides critical insights into target inhibition within tumor cells.

Key Insights:

  • The combination of FLT-PET and immunohistochemistry serves as a valuable tool for assessing drug efficacy in vivo.
  • Demonstrated target inhibition by PD0332991 in tumor cells, affecting proliferation and metabolism.
  • Provides a framework for evaluating other targeted therapies in hematologic malignancies.

Outlook:

  • Further validation of this imaging and biomarker strategy in larger clinical trials is warranted.
  • This approach can accelerate the development of new targeted therapies for lymphoma and other blood cancers.
  • Potential for improved patient stratification and personalized treatment strategies based on pharmacodynamic response.